Bosh sahifaEXEL • NASDAQ
add
Exelixis Inc
Yopilish kursi
34,50Â $
Kunlik diapazon
34,10Â $ - 36,19Â $
Yillik diapazon
20,02Â $ - 36,97Â $
Bozor kapitalizatsiyasi
10,29Â mlrd USD
Oʻrtacha hajm
1,94Â mln
Narx/foyda
22,95
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 539,54Â mln | 14,33% |
Joriy xarajat | 334,37Â mln | -28,97% |
Sof foyda | 117,97Â mln | 11Â 232,66% |
Sof foyda marjasi | 21,87 | 9Â 840,91% |
Har bir ulushga tushum | 0,47 | 370,00% |
EBITDA | 195,30Â mln | 1Â 830,28% |
Amaldagi soliq stavkasi | 23,77% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,19Â mlrd | 7,77% |
Jami aktivlari | 2,96Â mlrd | -0,56% |
Jami passivlari | 684,86Â mln | 8,83% |
Umumiy kapital | 2,28 mlrd | — |
Tarqatilgan aksiyalar | 285,58 mln | — |
Narxi/balansdagi bahosi | 4,33 | — |
Aktivlardan daromad | 16,38% | — |
Kapitaldan daromad | 19,62% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 117,97Â mln | 11Â 232,66% |
Operatsiyalardan naqd pul | 271,34Â mln | 131,19% |
Sarmoyadan naqd pul | -217,15Â mln | -726,05% |
Moliyadan naqd pul | 5,70Â mln | 102,59% |
Naqd pulning sof oʻzgarishi | 59,89 mln | 188,56% |
Boʻsh pul | 302,21 mln | 913,29% |
Haqida
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
Tashkil etilgan
15-noy, 1994
Sayt
Xodimlar soni
1Â 310
